Cognizant to Present at the Bank of America Securities 2025 Global Technology Conference
TEANECK, N.J., May 28, 2025 /PRNewswire/ -- Cognizant (Nasdaq: CTSH), a leading provider of information technology, consulting, and business process services, today announced a presentation at the following investor conference:
Bank of America Securities 2025 Global Technology Conference
A live audio webcast of the presentation will be available at Cognizant's website: http://investors.cognizant.com
A replay of the webcasts will remain available on the company's website for 90 days.
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.
Investor Contact:
Tyler Scott, Vice President, Investor Relations, (551) 220-8246, [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/cognizant-to-present-at-the-bank-of-america-securities-2025-global-technology-conference-302466142.html
SOURCE Cognizant Technology Solutions Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
The Best Top-Ranked Stocks to Buy in June
The S&P 500 jumped 6% last month for its best May since 1990 and its strongest monthly performance since November 2023. Meanwhile, the Nasdaq surged nearly 10% as Wall Street dove headfirst back into beaten-down technology stocks. The bulls pressed their advantage to start June, pushing the Nasdaq up 0.7% higher on Monday and 1% through midday trading Tuesday, boosted by strong showings from Nvidia and other tech giants. The bulls are in charge, fueled by tech earnings growth and trade war progress. Now they are attempting to break above a key trading range before they send the market to new all-time highs. It's time to explore how investors can use a Zacks screen to help find some of the best Zacks Rank #1 (Strong Buy) stocks to buy in June and throughout the summer of 2025. Zacks Rank #1 (Strong Buy) stocks outperform the market in good and bad times. However, there are over 200 stocks that earn a Zacks Rank #1 at any given time. Therefore, it's helpful to understand how to apply filters to the Zacks Rank in order to narrow the list down to a more manageable and tradable set of stocks. Clearly, there are only three items on this screen. But together, these three filters can result in some impressive returns. • Zacks Rank equal to 1 Starting with a Zacks Rank #1 is often a strong jumping off point because it boasts an average annual return of roughly 24.4% per year since 1988. • % Change (Q1) Est. over 4 Weeks greater than 0 Positive current quarter estimate revisions over the last four weeks. • % Broker Rating Change over 4 Week equal to Top # 5 Top 5 stocks with the best average broker rating changes over the last four weeks. This strategy comes loaded with the Research Wizard and is called bt_sow_filtered zacks rank5. It can be found in the SoW (Screen of the Week) folder. Here is one of the five stocks that qualified for the Filtered Zacks Rank 5 strategy today… OppFi's (OPFI) works with banks to provide financial products and services for 'everyday Americans' via its tech-enabled digital finance platform. OppFi partners with community banks to offer installment loans to middle-income Americans who are underserved by traditional financial institutions because of low credit scores and more. Image Source: Zacks Investment Research The company's digital OppLoans platform uses AI-driven underwriting to offer transparent, responsible lending with same-day funding. OppFi also supports financial education through partnerships to help customers improve their financial health. OppFi is projected to grow its earnings by 30% this year and 9% next year on 10% and 4%, respective revenue expansion. The financial services firm has crushed our bottom-line estimates by an average of 60% in the trailing four quarters, including a big beat-and-raise Q1 in early May. OppFi's recent upward earnings revisions are part of a much larger uptrend during the past year. Image Source: Zacks Investment Research OPFI stock has soared 300% in the past 12 months to crush its Business Services sector's 13%. Its recent outperformance is part of a 550% two-year run that's taken it above its summer 2021 levels after it went public via a SPAC. Despite the surge, investors can buy OppFi stock 22% below its February peaks while holding its ground above its 2021 IPO levels and its 21-day moving average recently. OppFi also trades at a 60% discount to its sector and 45% below its highs at 9.4X forward 12-month earnings. Get the rest of the stocks on this list and start looking for the newest companies that fit these criteria. It's easy to do. And it could help you find your next big winner. Start screening for these companies today with a free trial to the Research Wizard. You can do it. Click here to sign up for a free trial to the Research Wizard today. Want more articles from this author? Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published. Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks' portfolios and strategies are available at: Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OppFi Inc. (OPFI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
RxWellness Spine & Health Acquires AllCare Chiropractic & Injury, Expands Multi-Regional Footprint with Four New Maryland Clinics
HERNDON, Va., June 3, 2025 /PRNewswire/ -- RxWellness Spine & Health, the Mid-Atlantic's leading natural-first healthcare clinic network and platform for integrative care, today announced the strategic partnership and acquisition of AllCare Chiropractic & AllCare Injury, LLC. The transaction adds four established, high-performing clinics—Silver Spring, Baltimore (Federal Hill), Bowie, and Laurel—to the RxWellness family, deepening the company's reach across Washington D.C., Northern Virginia, and Maryland. This expansion marks a pivotal step in RxWellness's multi-state growth strategy, reinforcing its leadership in natural-first, integrated care. Patients across the region will now gain broader access to RxWellness's signature approach—an outcomes-focused model that blends chiropractic, rehabilitation, and regenerative therapies. With a proven framework for scalable integration and expansion through both de novo clinics and strategic acquisitions, RxWellness is uniquely positioned to meet the rising demand for drug-free, results-driven healthcare. "When we founded RxWellness, the mission was simple—deliver life-changing care that's natural, innovative, and rooted in results," said Dr. Philip Golinsky, CEO and Founder. "To now see that vision stretch into multiple states, reaching thousands more people who are seeking a better alternative to drugs or surgery—that's an incredible honor. And we're just getting started." RxWellness is not a traditional chiropractic chain. It is a natural-first, patient-first healthcare platform, built around The Prescription to Wellness®—a proprietary, three-phase model that provides immediate relief, targets root causes, and supports long-term health and vitality. The company integrates chiropractic care, rehabilitative therapy, and regenerative medicine in a seamless, personalized experience designed for both clinical outcomes and operational efficiency. "This partnership is the result of years of behind-the-scenes work from our incredible team," said Phoebe Casey, Chief Strategist and Chief Operating Officer. "From providers to operations, everyone brought their A-game to bring this to life. We're proud to now serve these Maryland communities and deliver on our promise: the highest standard of natural healthcare, at scale." With over 150,000 patients treated, 7,500+ five-star reviews, and features in Modern Luxury DC, ABC7's Good Morning Washington, and The Inc. 5000 (two-time honoree), RxWellness is attracting attention as a category-defining brand at the forefront of natural, non-surgical care. This expansion is part of a broader, disciplined growth strategy that includes: Scalable acquisition integration Strong regional density for brand equity and operational leverage Advanced backend systems to support shared services across locations RxWellness' purposeful and forward-thinking growth strategy is one designed to elevate the standard of care, broaden community access, and partner with leading clinics that align with the company's patient-first philosophy. As the company continues to grow, it remains focused on long-term value creation, with a vision to scale into a national leader in natural healthcare, underpinned by operational excellence, patient trust, and an unwavering mission: to elevate patient health and empower lives by providing natural care solutions for pain-free, drug-free living. About RxWellness Spine & HealthRxWellness Spine & Health is a nationally recognized healthcare organization specializing in non-surgical, natural pain relief and holistic wellness solutions. With a multidisciplinary approach that integrates chiropractic, rehabilitation, physical medicine, and regenerative therapies, RxWellness is redefining the standard for patient-centered care. The company's mission is to make natural healthcare the preferred path—not the alternative. For media inquiries or more information, contact:Dylan CaseyDirector of Marketingdylan@ View original content to download multimedia: SOURCE RxWellness Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company's global manufacturing strategy. TMS Yokohama will serve as a hub for commercial and clinical supply, and future research and development in the region. It expands Telix's global production network which includes in-house and partner facilities. Originally opened in 2018, the site comprises a cyclotron and multiple production hot cells and was designed and built by JFE Engineering Corporation (JFE) as the Contract Manufacturing Organization (CMO) for TLX250-CDx (Zircaix®[1], 89Zr-girentuximab) in Japan and China, including for the ZIRCON-CP study[2]. Taking over the lease and operational management of this facility will provide greater control over existing clinical supply with the possibility to expand production to other Telix investigational and future commercial products in the region, including Illuccix® (TLX591-CDx, 68Ga-PSMA-11) and Pixclara®1 (TLX101-CDx, 18F-floretyrosine) for Greater Tokyo, and TLX591 (177Lu rosopatamab tetraxetan) for the Asia Pacific region. Further, the Company plans to install Telix's ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, which it believes will facilitate standardized, high-efficiency and cost-effective production of commercially important medical isotopes. Darren Patti, Group Chief Operating Officer, Telix said, "We are pleased to announce Telix's first cyclotron facility in the Asia Pacific region, strategically located in Japan — the world's second-largest nuclear medicine market. TMS Yokohama enhances our capacity to meet growing demand in the region and supports our mission to provide patients with access to advanced diagnostic and therapeutic radiopharmaceuticals." About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the United States Food and Drug Administration (FDA)[1], by the Australian Therapeutic Goods Administration (TGA)[2], by Health Canada[3], by the Brazilian Health Regulatory Agency (ANVISA)[4], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[5], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[6] and in multiple countries within the European Economic Area (EEA)[7] following a positive decentralized procedure (DCP) opinion by the German medical regulator, BfArM[8]. TLX250-CDx, TLX101-CDx and TLX591 have not received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: [1] Telix ASX disclosure 20 December 2021. [2] Telix ASX disclosure 2 November 2021. [3] Telix ASX disclosure 14 October 2022. [4] Telix ASX disclosure 18 March 2025. [5] Telix ASX disclosure 13 February 2025. [6] Telix media release 29 April 2025. [7] Czech Republic, Denmark, Finland, Ireland, Luxembourg, Malta, the Netherlands, Norway and Sweden at time of release. [8] Telix ASX disclosure 17 January 2025. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. View original content to download multimedia: SOURCE Telix Pharmaceuticals Limited Sign in to access your portfolio
